

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	N/A 1/785,135
		Filing Date	February 24, 2004
		First Named Inventor	Rachel E. Meyers, et al.
		Group Art Unit	N/A 1643
		Examiner Name	N/A A.M. Harris, Ph.D.
Sheet 1 of 4	Attorney Docket Number	MPI00-022PIRDVIM	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T 2
amb	1	Chan, et al., (1996) "Apolipoprotein B mRNA Editing Protein: A Tool for Dissecting Lipoprotein Metabolism and a Potential Therapeutic Gene for Hypercholesterolemia," Gastroenterol. 34(3):31-31.	
	2	Chang, et al., (1998) "Evolutionary Analysis of RNA Editing Enzymes," Methods Companion Methods Enzymol. 15(1):41-50.	
	3	Eliopoulos et al., (1999) "Chemoprotection Against Cytosine Nucleoside Analogs Using the Human Cytidine Deaminase Gene," Prog. Exp. Tum. Res. 36:124-142.	
	4	Smith et al., (1996) "Base-Modification mRNA Editing Through Deamination - the Good, the Bad and the Unregulated," TIG 12(10):418-424.	
	5	Verweij, (1999) "Rational Design of New Tumoractivated™ Cytotoxic Agents," Oncology 57(1):9-15.	
	6	NCBI Accession No. AC002369, 22 January 1998.	
	7	NCBI Accession No. AL078593, 23 November 1999.	
	8	NCBI Accession No. G38167, 29 May 1998.	
amb	U	Amino Acid and Nucleic Acid Sequence Match Database Sheets, Document WO/9902546 (January 21, 1999)	
amb	U	Nucleic acid and Amino Acid Database Sheets, Accession Number A1435527, April 13, 1999	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	N/A 10/985, 135
		Filing Date	February 24, 2004
		First Named Inventor	Rachel E. Meyers, et al.
		Group Art Unit	N/A 1643
		Examiner Name	N/A A.M. Harris, Ph.D.
		Attorney Docket Number	MPI00-022PIRDVIM
Sheet	2	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
amh	U	Kappel et al, Regulating Gene Expression in Transgenic Animals, Current Opinion in Biotechnology 3: 548-553, 1992.	
	U	Mullins and Mullins., Perspective Series: Molecular Medicine in Genetically Engineered Animals, J. Clin. Invest. 98(11): S37-S40, 1996.	
	U	Mullins et al., Fulminant Hypertension in Transgenic Rats Harboring the Mouse Ren-2 Gene. Nature 344: 541-544, April 5, 1990	
	V	Houdebine, Production of Pharmaceutical Proteins from Transgenic Animals. Journal of Biotechnology 34:269-287, 1994.	
	V ₂	Rieger et al., Glossary of Genetics and Cytogenetics: Classical and Molecular, Fourth Completely Revised Edition, Springer-Verlag, New York, pages 17 and 18, 1976.	
	V	Taurog et al., HL-B27 in Inbred and Non-Inbred Transgenic Mice. The Journal of Immunology 141(11): 4020-4023, December 1, 1988.	
	V	Mullins and Mullins, Transgenesis in Nonmurine Species, Hypertension 22: 630-633, 1993	
	W	Wall, R.J., Transgenic Livestock: Progress and Prospects for the Future. Theriogenology 45: 57-68, 1996	
	W ₂	Lazar et al., Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Molecular and Cellular Biology 8(3): 1247-1252, March 1988.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	N/A 10 785, 135
		Filing Date	February 24, 2004
		First Named Inventor	Rachel E. Mcycrs, et al.
		Group Art Unit	N/A 1643
		Examiner Name	N/A A. M. Harris, Ph.D.
Sheet 3 of 4	Attorney Docket Number	MPI00-022P1RDVIM	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
amh	W	Mullins, et al., Expression of the DBA/2J Ren-2 Gene in the Adrenal Gland of Transgenic Mice. The EMBO Journal 8(13): 4065-4072, 1989.	
	W	Niemann, H., Transgenic Farm Animals get off the Ground. Transgenic Research 7: 73-75, 1998.	
	X	Overbeek, Paul A., Transgenic Phenomenology Within Transgenic Animal Technology, A Laboratory Handbook Edited by Carl A. Pinkert, 1994.	
	X	Hammer, et al., Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human Beta(2)Microglobulin: An Animal Model of HLA-B27-Associated Human Disorders. Cell 63:1099-1112, November 30, 1990.	
	X	Niemann, H., Transgenic Farm Animals Get off the Ground. Transgenic Research 7: 73-75, 1998	
	X	Cameron, Ewan R., Recent Advances in Transgenic Technology. Molecular Biotechnology 7: 253-265, 1997	
	14	Somasekaram, A., et al., "Intracellular Localization of Human Cytidine Deaminase, Identification of a Functional Nuclear Localization Signal," The Journal of Biological Chemistry, 1999, pp. 28405-28412, Vol. 274(40).	
	15	Weiner, K., et al., "Primary Structure of Human Deoxycytidylate Deaminase and Overexpression of its Functional Protein in Escherichia coli," The Journal of Biological Chemistry, 1993, pp. 12983-12989, Vol. 268(17).	
	16	EMBL Database Report for Accession No. AL138875, February 5, 2000 (XP-002186947)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	NA 10/785,135
		Filing Date	February 24, 2004
		First Named Inventor	Rachel E. Meyers, et al.
		Group Art Unit	NA 1643
		Examiner Name	NA A. M. Harris, Ph.D.
Sheet 4 of 4	Attorney Docket Number	MPI00-022PIRDVIM	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
amh	17	EMBL Database Report for Accession No. AI435527, March 16, 1999 (XP-002186948)	
	18	EMBL Database Report for Accession No. AI767392, June 30, 1999 (XP-002186949)	
V	19	EMBL Database Report for Accession No. AWO73866, October 18, 1999 (XP-002186950)	
	20	EMBL Database Report for Accession No. AI142574, September 28, 1998 (XP-002186951)	
	21	EMBL Database Report for Accession No. BF114724, October 26, 2000 (XP-002186952)	
	22	EMBL Database Report for Accession No. Q9WYN5, November 12, 1999 (XP-002186953)	
Examiner Signature	amh Harris		Date Considered 09/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not yet Assigned 10/785,135
				Filing Date	February 24, 2004
				First Named Inventor	Rachel E. Meyers, et al.
				Group Art Unit	MA 1643
				Examiner Name	AM A.M. HARRIS, Ph.D.
Sheet	1	of	1	Attorney Docket Number	MPI00-022PIRDVIM

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AM	9	US 5,622,851		Maley, F. et al.	04-22-1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
amh	10	WO	97/05254	A1	Centre de Recherche de L-Hopital	02-13-1997		
↓	11	WO	98/45472	A1	Harosh, I.	10-15-1998		
	12	WO	99/02546	A1	Human Genome Sciences, Inc	01-21-1999		
	13	EP	1,033,401	A2	Genset	09-06-2000		

Examiner Signature	AM Harris	Date Considered	09/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rachel E. Meyers and Laura A. Rudolph-Owen
Divisional Application N/A Group No.: Not Yet Assigned
of Application No.:
Filed: February 24, 2004 Examiner: Not Yet Assigned
For: 26934, A NOVEL CYTIDINE DEAMINASE-LIKE MOLECULE AND USES
THEREOF

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:
☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No. EV407135238US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: February 24, 2004


Signature

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.